NCT01904136 - Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2014

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Gene MutationsBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positivede Novo Myelodysplastic SyndromeMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveTherapy-Related Acute Myeloid Leukemia

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSC or bone marrow transplant

PROCEDURE

Bone Marrow Transplantation

Undergo allogeneic PBSC or bone marrow transplant

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

BIOLOGICAL

Natural Killer Cell Therapy

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC or bone marrow transplant

DRUG

Tacrolimus

Given IV and PO

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER